Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29893282 | 1.00 | GPR3 (0.41) | GPR3HTR2APOLBHDAC3HDAC4 | |
| Toluene SCHEMBL28351667 | 0.87 | LMNA (0.44) | GPR3HTR2APOLBKMT2AACHE | |
| SCHEMBL6421466 | 0.78 | GPR3 (0.44) | GPR3HTR2APOLBHDAC3HDAC4 | |
| SCHEMBL29711937 | 0.74 | GPR3 (0.41) | GPR3HTR2APOLBHDAC3HDAC4 | |
| SCHEMBL1766205 | 0.74 | GPR3 (0.46) | GPR3HTR2APOLBHDAC3HDAC4 | |
| SCHEMBL1568290 | 0.74 | GPR3 (0.46) | GPR3HTR2APOLBHDAC3HDAC4 | |
| SCHEMBL224931 | 0.74 | GPR3 (0.41) | GPR3HTR2APOLBHDAC3HDAC4 | |
| SCHEMBL1766128 | 0.74 | GPR3 (0.41) | GPR3HTR2APOLBHDAC3HDAC4 | |
| SCHEMBL7421342 | 0.74 | GPR3 (0.41) | GPR3HTR2APOLBHDAC3HDAC4 | |
| SCHEMBL29196425 | 0.74 | GPR3 (0.41) | GPR3HTR2APOLBHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055993-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3941924-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | Wave Life Sciences Ltd. (SG) | 2022-01-26 | — | — | EP | disclosed |
| EP-3891284-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2021-10-13 | — | — | EP | disclosed |
| WO-2021071788-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-04-15 | — | — | WO | disclosed |
| EP-3790596-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Wave Life Sciences Ltd. (SG) | 2021-03-17 | — | — | EP | disclosed |
| WO-2020227691-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020191252-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020118246-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-11 | — | — | WO | disclosed |
| EP-3658576-A1 | ANTICANCER PEPTIDES | IDP Discovery Pharma, S.L. (ES) | 2020-06-03 | — | — | EP | disclosed |
| WO-2019217784-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019020649-A1 | ANTICANCER PEPTIDES | IDP DISCOVERY PHARMA, S.L. (ES) | 2019-01-31 | — | — | WO | disclosed |
| WO-2018053373-A1 | USES OF SATL-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055993-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | MKI67, PCNA, VHL | GPR3 4254/4885HTR2A 3403/4885POLB 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.